197 related articles for article (PubMed ID: 23278987)
1. Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy.
Bosch W; Poowanawittayakom N; Chaikriangkrai K; Mendez J; Hellinger WC; Gonwa TA; Krishna M; Pungpapong S
Transpl Infect Dis; 2013 Feb; 15(1):E33-9. PubMed ID: 23278987
[TBL] [Abstract][Full Text] [Related]
2. Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction.
Baghban A; Azar MM; Bernardo RM; Malinis M
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27852682
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induction in deceased donor kidney transplantation.
Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
[TBL] [Abstract][Full Text] [Related]
4. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.
Peleg AY; Husain S; Kwak EJ; Silveira FP; Ndirangu M; Tran J; Shutt KA; Shapiro R; Thai N; Abu-Elmagd K; McCurry KR; Marcos A; Paterson DL
Clin Infect Dis; 2007 Jan; 44(2):204-12. PubMed ID: 17173218
[TBL] [Abstract][Full Text] [Related]
5. Opportunistic infections complicating solid organ transplantation with alemtuzumab induction.
Helfrich M; Ison MG
Transpl Infect Dis; 2015 Oct; 17(5):627-36. PubMed ID: 26228653
[TBL] [Abstract][Full Text] [Related]
6. Rapidly growing non-tuberculous mycobacterial infection in a renal transplant patient after alemtuzumab induction.
Hazara AM; Edey M; Roy A; Bhandari S
Transpl Infect Dis; 2014 Oct; 16(5):847-52. PubMed ID: 25040696
[TBL] [Abstract][Full Text] [Related]
7. Nontuberculous mycobacterial pulmonary infection in renal transplant recipients.
Ho TA; Rommelaere M; Coche E; Yombi JC; Kanaan N
Transpl Infect Dis; 2010 Apr; 12(2):138-42. PubMed ID: 19929882
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
9. Successful kidney re-transplantation in a patient with previous allograft kidney tuberculosis.
Siu YP; Tong MK; Leung KT; Yung CY
Transpl Infect Dis; 2004 Sep; 6(3):132-5. PubMed ID: 15569231
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
11. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study.
Safdar N; Smith J; Knasinski V; Sherkow C; Herrforth C; Knechtle S; Andes D
Diagn Microbiol Infect Dis; 2010 Jan; 66(1):7-15. PubMed ID: 19963164
[TBL] [Abstract][Full Text] [Related]
12. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation.
Walsh R; Ortiz J; Foster P; Palma-Vargas J; Rosenblatt S; Wright F
Transpl Infect Dis; 2008 Jul; 10(4):236-9. PubMed ID: 18086280
[TBL] [Abstract][Full Text] [Related]
13. Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience.
Florescu DF; Seaman JA; Kalil AC; Qiu F; Bremers D; Westphal SG
Transplant Proc; 2021 Apr; 53(3):1058-1063. PubMed ID: 32921434
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium bovis disease in a pediatric renal transplant patient.
Chen SF; Gutierrez K
Pediatr Infect Dis J; 2006 Jun; 25(6):564-6. PubMed ID: 16732161
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis in solid-organ transplant recipients: disease characteristics and outcomes in the current era.
Sun HY; Munoz P; Torre-Cisneros J; Aguado JM; Lattes R; Montejo M; Garcia-Reyne A; Bouza E; Valerio M; Lara R; Wagener MM; John GT; Bruno D; Singh N
Prog Transplant; 2014 Mar; 24(1):37-43. PubMed ID: 24598564
[TBL] [Abstract][Full Text] [Related]
18. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and outcome of tuberculosis in solid organ transplant recipients.
Hsu MS; Wang JL; Ko WJ; Lee PH; Chou NK; Wang SS; Chu SH; Chang SC
Am J Med Sci; 2007 Aug; 334(2):106-10. PubMed ID: 17700199
[TBL] [Abstract][Full Text] [Related]
20. A 10-year experience of tuberculosis in solid-organ transplant recipients.
Ulubay G; Kupeli E; Duvenci Birben O; Seyfettin EP; Dogrul MI; Ozsancak Ugurlu A; Oner Eyuboglu F; Haberal M
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():214-8. PubMed ID: 25894157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
